Parkinsons and Movement Disorders

Novel Insights and Therapeutics for Parkinson’s disease

Parkinson’s disease is the essential growth driver of the worldwide Parkinsons disease therapeutics. Most mutations such as SNCA, PINK1, PARK2, PARK7, PLA2G6, FBXO7 and ATP13A2 are the rare cause of the disease and one particular mutation in LRRK2 has been found common in certain populations. The enzymatic function of the mitochondrial localized kinase PINK1 is thereby essential and delivers a fast production of Parkin from its uniform distribution in the cytoplasm to damaged mitochondria. Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement. The therapeutics of Parkinsons Disease includes designing a Clinical trial for Parkinson, Outcome of clinical trials in PSP, therapeutic options for mood, Cognition and Psychosis. Physical therapy cannot cure Parkinson’s disease but therapy can help to compensate the changes brought about by the condition, physical therapy can help with balance problems, fatigue, pain, weakness and sometimes local heat application is produced with high frequency to relieve muscle aches and pain.